To further evaluate if MBZ is a suitable therapeutic agent to inhibit GLI, we transferred these findings into the clinical setting by treating two refractory AML patients with MBZ monotherapy in an off-label setting. This evidence concerns the gene GLI1 and acute myeloid leukemia.